Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

(2019) Josef Coresh et al.   Lancet Diabetes & Endocrinology

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

(2019) Hiddo J L Heerspink et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study

(2019) Sadayoshi Ito et al.   JOURNAL OF HUMAN HYPERTENSION

Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects

(2018) Manabu Kato et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease

(2018) Akira Nishiyama   HYPERTENSION RESEARCH

Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?

(2017) Ali Nehme et al.   HYPERTENSION RESEARCH

High Glucose Stimulates Mineralocorticoid Receptor Transcriptional Activity Through the Protein Kinase C β Signaling

(2017) Takeshi Hayashi et al.   International Heart Journal

Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium

(2016) George C. Roush et al.   JOURNAL OF HYPERTENSION

Safety and Antihypertensive Effect of Selara® (Eplerenone): Results from a Postmarketing Surveillance in Japan

(2016) Shoko Takahashi et al.   International Journal of Hypertension

Effects of Additive Therapy With Spironolactone on Proteinuria in Diabetic Patients Already on ACE Inhibitor or ARB Therapy

(2016) Mohammad G. Saklayen et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Aldosterone Blockade in CKD: Emphasis on Pharmacology

(2015) Michael H. Schwenk et al.   ADVANCES IN CHRONIC KIDNEY DISEASE

Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial

(2015) Sawako Kato et al.   Clinical and Experimental Nephrology

Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View

(2015) H. J. Lambers Heerspink et al.   Clinical Journal of the American Society of Nephrology

Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis

(2015) Jing Hou et al.   CLINICAL THERAPEUTICS

CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats

(2015) Kiyoshi Arai et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

The renal effects of mineralocorticoid receptor antagonists

(2015) Stefano Bianchi et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone

(2015) Mitja Lainscak et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: Systematic review and meta-analysis

(2014) Francesco Pelliccia et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Local Mineralocorticoid Receptor Activation and the Role of Rac1 in Obesity-Related Diabetic Kidney Disease

(2014) Shigetaka Yoshida et al.   NEPHRON EXPERIMENTAL NEPHROLOGY

2013 ESH/ESC Guidelines for the management of arterial hypertension

(2013)   EUROPEAN HEART JOURNAL

Nifedipine controlled-release 40 mg b.i.d. in Japanese patients with essential hypertension who responded insufficiently to nifedipine controlled-release 40 mg q.d.: a phase III, randomized, double-blind and parallel-group study

(2013) Kazuaki Shimamoto et al.   HYPERTENSION RESEARCH

Mineralocorticoid Receptor-Associated Hypertension and Its Organ Damage: Clinical Relevance for Resistant Hypertension

(2012) H. Shibata et al.   AMERICAN JOURNAL OF HYPERTENSION

Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors

(2012) Amy McCurley et al.   NATURE MEDICINE

The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease

(2011) Nicola C. Edwards et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure

(2010) Aurelie Nguyen Dinh Cat et al.   FASEB JOURNAL

Treatment of resistant hypertension

(2010) Eduardo Pimenta et al.   JOURNAL OF HYPERTENSION

Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy

(2009) U. F. Mehdi et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Change in Proteinuria After Adding Aldosterone Blockers to ACE Inhibitors or Angiotensin Receptor Blockers in CKD: A Systematic Review

(2008) Andrew S. Bomback et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Retrospective Review of the Frequency of ECG Changes in Hyperkalemia

(2008) B. T. Montague et al.   Clinical Journal of the American Society of Nephrology

Resistant Hypertension: Diagnosis, Evaluation, and Treatment

(2008) David A. Calhoun et al.   HYPERTENSION

Rapid responses to aldosterone in the kidney and colon

(2007) Brian J. Harvey et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY